Lytix Biopharma, a Scandinavian drug development company, intends to conduct clinical trials for its lead anti-cancer molecule, LTX-315. This step furthers the company’s research into synthetic peptides through the identification of effective and selective lead molecules for the treatment of cancer. The company has teamed up with Bachem and Fulcrum to ensure that the drug development process faces no further delays.